COURT-RULING ·Filed Mar 30, 2026

GERN

Geron Corporation
NEUTRAL
Impact 2/10
Horizonweeks Processed6mo ago CourtView Ruling on CourtListener
Actionable Insight • Neutral

Monitor for future docket updates and actual court opinions; these filings suggest potential shareholder litigation risk, but without content, the merits or exposure cannot be assessed.

DirectionNeutral
Confidencelow
Horizonweeks
Final — all horizons settled through T+60d
GERN ▼ -2.84% at T+60d
NEUTRAL call ✗ call lost -2.84% · α vs SPY -19.33% · entry $1.41 → $1.37
Entry anchored
Mar 27, 03:59 PM ET
via exchange tick
T+1d
+5.67%
call +5.67% · α +2.78%
$1.49
settled 6mo ago
T+5d
+23.40%
call +23.40% · α +19.10%
$1.74
settled 6mo ago
T+20d
+7.09%
call +7.09% · α -5.50%
$1.51
settled 5mo ago
T+60d
-2.84%
call -2.84% · α -19.33%
$1.37
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

Analysis based on filing metadata only — document content was unavailable

Court Ruling Details

Court
United States District Court for the Northern District of California
Court Level
District
Case Type
securities fraud
Ruling Type
other
Outcome
PARTIAL — mixed ruling, some claims won/lost
Will It Be Appealed?
N/A (final)
Precedent Risk
LOW

Key Facts

  • Three derivative and securities-related lawsuits were filed against Geron Corporation in the U.S. District Court for the Northern District of California on March 30, 2026.
  • Case numbers: 3:25-cv-08575 (Hyung v. Geron), 3:25-cv-03356 (In re Geron Corporation Derivative Litigation), and 3:25-cv-02563 (Potvin v. Geron).
  • No substantive ruling text is available — only PACER login redirects are present in the documents.

Financial Impact

Unknown — no financial terms or damages disclosed

Risk Factors

  • Potential for material shareholder litigation if allegations involve undisclosed adverse events or misleading disclosures
  • Risk of increased legal expenses and management distraction if cases proceed

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 3 court opinions from CourtListener.

DocumentAccession Number
COURT-RULING Data (Synthetic)court-35h6ngfo-GERN
COURT-RULING Data (Synthetic)court-hharbx1z-GERN
COURT-RULING Data (Synthetic)court-21dsdcox-GERN
4 reports for GERN
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for GERN — sortable, filterable
TypeNow
Apr 22, 2026
23w ago
Press Release
NEUTRAL ★ 3/10
$1.55 $1.44▼ −7.10%▼ −11.88%$1.22 (−21.61%)
Apr 7, 2026
25w ago
DEFA14A
NEUTRAL ★ 3/10
$1.71 $1.36▼ −20.47%▼ −30.92%$1.22 (−28.95%)
Mar 30, 2026
26w ago
Court Ruling
NEUTRAL ★ 2/10
$1.41 $1.37▼ −2.84%▼ −19.33%$1.22 (−13.83%)
Feb 25, 2026
31w ago
8-K
BULLISH ★ 7/10
$1.72 $1.26▼ −26.74%▼ −33.69%$1.22 (−29.36%)
Showing 4 of 4

US Market Status

Market Open — Closes in 2h 17m

Subscribe to SecBot

Get Real-Time Court Ruling Intelligence

Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more — parsed and scored by AI.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access